(Q38286217)

1 September 2017

1 reference

title

Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance (English)

1 reference

1 September 2017

4

Gertjan J L Kaspers

1 reference

1 September 2017

6

Jacqueline Cloos

1 reference

1 September 2017

Anna Wojtuszkiewicz

1

1 reference

1 September 2017

Yehuda G Assaraf

series ordinal

2

1 reference

1 September 2017

Marielle J P Maas

series ordinal

3

1 reference

1 September 2017

Gerrit Jansen

series ordinal

5

1 reference

1 September 2017

language of work or name

English

0 references

publication date

13 December 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

1 September 2017

1 reference

1 September 2017

11

1 reference

1 September 2017

5

1 reference

1 September 2017

673-689

1 reference

Spliced segments at the 5′ terminus of adenovirus 2 late mRNA

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

An amazing sequence arrangement at the 5' ends of adenovirus 2 messenger RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Expansion of the eukaryotic proteome by alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The spliceosome: design principles of a dynamic RNP machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Architectural limits on split genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Pre-mRNA splicing and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Genomic medicine--a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Spliceosome Structure and Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Understanding alternative splicing: towards a cellular code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Alternative splicing and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Context-dependent control of alternative splicing by RNA-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Understanding splicing regulation through RNA splicing maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Neuronal regulation of alternative pre-mRNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Listening to silence and understanding nonsense: exonic mutations that affect splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Transcript dynamics of proinflammatory genes revealed by sequence analysis of subcellular RNA fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for lncRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Pause locally, splice globally

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Splicing in disease: disruption of the splicing code and the decoding machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Splicing in oncogenesis and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The connection between splicing and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The isoforms of the p53 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The gene encoding the splicing factor SF2/ASF is a proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The emerging role of splicing factors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Splice variants as cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Clinical and biological implications of driver mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

mRNA splicing variants: exploiting modularity to outwit cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Regulation of apoptosis by alternative pre-mRNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

U2AF-homology motif interactions are required for alternative splicing regulation by SPF45

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Comprehensive overview of the structure and regulation of the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Human SPF45, a Splicing Factor, Has Limited Expression in Normal Tissues, Is Overexpressed in Many Tumors, and Can Confer a Multidrug-Resistant Phenotype to Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Regulation of chemoresistance via alternative messenger RNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Serine-Arginine-rich Protein p30 Directs Alternative Splicing of Glucocorticoid Receptor Pre-mRNA to Glucocorticoid Receptor β in Neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Oncogenic H-ras reprograms Madin-Darby canine kidney (MDCK) cell-derived exosomal proteins following epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

The spliceosome as a target of novel antitumour drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Splicing factor SF3b as a target of the antitumor natural product pladienolide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Sudemycin E influences alternative splicing and changes chromatin modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Modulation of RNA splicing as a potential treatment for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Splice modulating therapies for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

RNA splicing: disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Antitumorigenic potential of STAT3 alternative splicing modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Anti-tumor activity of splice-switching oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Eteplirsen for the treatment of Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Identification of genes associated to 2',2'-difluorodeoxycytidine resistance in HeLa cells with a lentiviral short-hairpin RNA library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Global Analysis of Nascent RNA Reveals Transcriptional Pausing in Terminal Exons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

Gene Expression: The Close Coupling of Transcription and Splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.993316

10.1517/17425255.2015.993316

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference